Double‐blind randomized controlled trial comparing misoprostol and oxytocin for management of the third stage of labor in a Nigerian hospital

Musa, Abdulkarim O.; Ijaiya, Munirdeen A; Saidu, Rakiya; Aboyeji, Abiodun P.; Jimoh, Abiodun A.; Adesina, Kikelomo T; Abdul, IF

doi:10.1016/j.ijgo.2015.01.008

Cited by 15 publications

(22 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Musa [13] 325.85 ± 164.72 ml 303.95 ± 163.33 0.391 Open Journal of Obstetrics and Gynecology the main side effects found in our study. These are known side effects of prostaglandins by central action, as well as nausea and vomiting [18] [19] [20].…”

Section: Authorssupporting

confidence: 47%

Efficiency and Tolerance of Misoprostol versus Oxytocin in the Active Management of the Third Period of Delivery at the University Maternity Porto-Novo, Benin

Aguèmon¹,

Ogoudjobi²,

Symphorose³

et al. 2018

OJOG

View full text Add to dashboard Cite

Objective: To assess the efficiency and tolerance of misoprostol versus oxytocin in Active Management of the Third Period of Childbirth. Framework and Method of Study: The study was carried out at the Porto-Novo university maternity in Benin. The hospital is level 3. He acted in a randomized clinical trial with a descriptive and comparative aim referred from 1st January 2017 to 31st December 2017. We included all eligible women in labor in the delivery room during the study period and at that gestational age was greater than or equal to 37 weeks of amenorrhea, delivery was done through vaginal birth and delivered with a live birth and agreed to participate in the study. The cases eligible by order of admission were grouped in blocks of two, "Misoprostol" and "Oxytocin" corresponding to the Active Management of the Third Period of delivery. The data collected were captured and analyzed using the SPSS version 20 software. For the comparison of the results, we used the chi-square statistical test and the difference was assumed to be statistically significant for a p ≤ 0.05. The confidentiality of parturient was respected. Results: we recorded 1234 of which were delivered via vaginal birth. The Active Management of the Third Period of Delivery was carried out in 1202 parturients. According to our inclusion criteria, 892 parturients were retained for the study, of which 446 for each group. The average age of parturients was 26.94 ± 5.65 years. Almost pregnancies were mono-fetal (95.7% vs. 93.5%). The average time to expel the placenta after utero-tonic administration was 4.05 ± 0.27 min in the "Misoprostol" group versus 3.82 ± 0.52 min in the "Oxytocin" group (p > 0.05). We had only 9 cases of placental retention in the group "Misoprostol" versus 5 cases in the "Oxytocin" group. Most of the parturients had blood loss 322 Open Journal of Obstetrics and Gynecology less than 500 ml (96.2% vs. 96.6%). The frequency of delivery hemorrhage was 3.8% in the "Misoprostol" group versus 3.4% in the "Oxytocin" group. The mean blood volume lost was 284.33l ± 13.31 ml in the "Misoprostol" group versus 225.94 ± 21.52 ml in the "oxytocin" group. Maternal prognosis was generally good in both groups. Conclusion: Misoprostol may be an alternative in Active Management of the Third Period of Delivery especially in developing countries where the cold chain is often lacking.

show abstract

Section: Authorssupporting

confidence: 47%

Efficiency and Tolerance of Misoprostol versus Oxytocin in the Active Management of the Third Period of Delivery at the University Maternity Porto-Novo, Benin

Aguèmon¹,

Ogoudjobi²,

Symphorose³

et al. 2018

OJOG

View full text Add to dashboard Cite

show abstract

“…Misoprostol, in addition to its role in managing miscarriages, pre-induction cervical ripening, and induction of labor, prevention and treatment of primary postpartum hemorrhage has gained relevance in myomectomy (14). It increases myometrial contractions thereby reducing uterine artery blood flow to the uterus (15).…”

Section: Introductionmentioning

confidence: 99%

Comparing perioperative vaginal misoprostol with intraoperative pericervical hemostatic tourniquet in reducing blood loss during abdominal myomectomy: A randomized controlled trial

Afolabi¹,

Ezeoke²,

Saidu³

et al. 2019

J Turkish German Gynecol Assoc

Self Cite

View full text Add to dashboard Cite

Objective: To compare the effectiveness of perioperative vaginal misoprostol with intraoperative pericervical hemostatic tourniquet in reducing blood loss during abdominal myomectomy. Material and Methods: A randomized controlled trial involving women with uterine leiomyoma who underwent abdominal myomectomy was conducted at a tertiary facility in Nigeria. Participants were recruited after they gave informed consent and randomized into group I (single dose 400 μg vaginal misoprostol one-hour before surgery) and group II (intraoperative pericervical hemostatic tourniquet). Eighty participants (40 in each group) were recruited. Uterine size was measured in centimeters above the pubic symphysis, and blood loss estimation involved direct volume measurement and gravimetric methods. The main outcome measures were intraoperative blood loss, blood transfusion, and recourse to hysterectomy. Ethical approval and trial registration were obtained; the data were analyzed using the SPSS software version 21.0; p<0.05 was considered significant. Results: Participants in group I had higher mean intraoperative blood loss (931.89±602.13 vs 848.40±588.85 mL, p=0.532), intra-operative blood transfusion rates (60 vs 55%; p=0.651) and mean units of blood transfused (1.30±1.20 vs 1.20±1.30; p=0.722) compared with group II. The mean uterine size (19.50±6.93 vs 20.05±6.98 cm; p=0.725) and number of fibroid nodules (11.25±7.99 vs 11.45±8.22; p=0.912) were comparable. The change in post-operative hematocrit was 2.66±2.21% vs 3.24±2.85% (p=0.315) and post-operation blood transfusion was 2.5 vs 5% (p=0.556). There was no recourse to hysterectomy in either of the study groups. While adverse effects of misoprostol occurred in 5 (12.5%) participants of group I. Conclusion: The effectiveness of perioperative vaginal misoprostol is comparable to intra-operative hemostatic pericervical tourniquet in reducing blood loss during abdominal myomectomy.

show abstract

“…Once the tourniquet is removed, there is bleeding from the raw myometrium and cavities with possibility of increased blood loss and blood transfusion (13). Misoprostol in addition to its role in managing miscarriages, pre-induction cervical ripening, and induction of labor, prevention and treatment of primary postpartum hemorrhage (14) has gained relevance in myomectomy. It increases myometrial contractions thereby reducing uterine artery blood flow (15) to the uterus.…”

Section: Introductionmentioning

confidence: 99%

Comparing perioperative vaginal misoprostol to intraoperative pericervical hemostatic tourniquet in reducing blood loss during abdominal myomectomy: a randomized controlled trial

Afolabi¹,

Ezeoke²,

Saidu³

et al. 2018

J Turkish German Gynecol Assoc

Self Cite

View full text Add to dashboard Cite

Double‐blind randomized controlled trial comparing misoprostol and oxytocin for management of the third stage of labor in a Nigerian hospital

Cited by 15 publications

References 15 publications

Efficiency and Tolerance of Misoprostol versus Oxytocin in the Active Management of the Third Period of Delivery at the University Maternity Porto-Novo, Benin

Efficiency and Tolerance of Misoprostol versus Oxytocin in the Active Management of the Third Period of Delivery at the University Maternity Porto-Novo, Benin

Comparing perioperative vaginal misoprostol with intraoperative pericervical hemostatic tourniquet in reducing blood loss during abdominal myomectomy: A randomized controlled trial

Comparing perioperative vaginal misoprostol to intraoperative pericervical hemostatic tourniquet in reducing blood loss during abdominal myomectomy: a randomized controlled trial

Contact Info

Product

Resources

About